Navigation Links
PeriCor Therapeutics Reports Positive Preclinical Results of GP531 at the European Heart Failure Congress in Nice
Date:6/3/2009

represents a novel cardioprotective approach with a unique mechanism of action that addresses key functional maladaptations responsible for the worsening heart failure state." "The beneficial effects of GP531 were remarkably consistent within this study," noted David G. Shand, M.D., Ph.D., Senior Advisor for Clinical and Scientific Affairs. "The findings provide important insights for further evaluation of GP531 in heart failure." Results from these studies should be reported later this year and early next year. Richard Stover, President and CEO of PeriCor Therapeutics, Inc., added, "We are confident that these studies will provide additional insights into this novel approach to improve global myocardial function in patients with heart failure, and we plan to initiate a Phase II study of GP531 in acute decompensated heart failure during the second half of the year."

About GP531

GP531 is an adenosine regulating agent (ARA) that has been shown to amplify the body's broad-spectrum protective response -- the localized release of endogenous adenosine -- during episodes of cellular stress. Cellular stress, as occurs with ischemia and tissue hypoxia, triggers the breakdown of adenosine triphosphate (ATP). ATP is the key energy molecule of living cells. Endogenous adenosine has been termed a "retaliatory metabolite" that targets multiple pathways of cellular stress and myocardial injury to counter net ATP catabolism and, as such, acts as a key regulator of cellular energetics. Endogenous adenosine protects cells from multiple pathways of injury such as inflammation, apoptosis and necrosis. Endogenous adenosine levels have been shown to be elevated in heart failure patients but not sufficiently to be cardioprotective.

By augmenting a patient's own adenosine release in stressed tissues of the heart and its microvasculature, GP531 may have the potential to protect the heart muscle from further damage, alter the deterioration of
'/>"/>

SOURCE PeriCor Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. PeriCor Therapeutics Appoints K. Tucker Andersen to Board of Directors
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
5. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
6. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
7. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
8. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
9. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
11. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... (PRWEB) November 25, 2014 Continuing its ... products, earned three prestigious MarCom Awards for outstanding creative ... received a Platinum MarCom Award, the organization’s top honor, ... in St. Louis held in April of this year. ... than 14,000 attendees. Additionally, Nerium was awarded a Gold ...
(Date:11/26/2014)... SoundConnect , an award winning unified communications ... Darren Suders has joined the team as Director of ... partner program through innovative offerings, consistent partner ... brings more than 10-years of channel telecommunication experience to ... from policy development, to partner education and to expansion. ...
(Date:11/26/2014)... MINNEAPOLIS , Nov. 25, 2014 Bio-Techne ... it has appointed Robert Gavin to serve ... of the Protein Platforms Division.  Mr. Gavin will be ... business segment, which includes the ProteinSimple business acquired in ... San Jose, California -based ProteinSimple ...
(Date:11/24/2014)... 2014 Five American winners will ... Maktoum Awards for Medical Sciences", in its 8 th ... Emirates , on 15 December 2014. ... The Carter Center which won the Hamdan Award for ... numerous programs that aim to improve health and promote ...
Breaking Biology Technology:Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2SoundConnect Appoints Director of Channel Development & Sales 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3Five US Winners Among Recipients of Hamdan Medical Awards 2
... Advances in biotechnology and life science research coupled with broader range ... culture market. Growth is likely to be fueled by heightened interest ... of industrial biopharmaceuticals. , ... San Jose, CA (PRWEB) ...
... today the,submission of the response to the FDA ... Single Dose Containers). In an,Approvable Letter received on ... respect to chemistry, manufacturing, and controls (CMC)., ... response as a Class 2,resubmission, under which the ...
... Calif., Nov. 5 Telik, Inc.,(Nasdaq: TELK ) ... per share, for,the third quarter ended September 30, 2008, ... per share, for the comparable period in 2007. The,$8.0 ... to,corporate and municipal notes investments with an auction reset ...
Cached Biology Technology:Cell/Tissue Culture Supplies Market to Reach $4.97 Billion by 2012, According to New Report by Global Industry Analysts 2Cell/Tissue Culture Supplies Market to Reach $4.97 Billion by 2012, According to New Report by Global Industry Analysts 3SALVAT Announces Submission of Complete Response to FDA Approvable Letter for CETRAXAL(R) 2Telik Announces Financial Results for 2008 Third Quarter 2Telik Announces Financial Results for 2008 Third Quarter 3Telik Announces Financial Results for 2008 Third Quarter 4
(Date:11/3/2014)... 2014 Research and Markets has announced ... Technologies, Markets and Companies" to their offering. ... methods, which have already started to play an important role ... replacing the old fashioned bone marrow transplants. Role of cells ... to become a part of medical practice. Stem ...
(Date:11/3/2014)... 3, 2014  NeuroSigma ® , Inc. (NeuroSigma), ... company focused on commercialization of its non-invasive ... treatment of neurological and neuropsychiatric disorders, announced today ... issued a Notice of Allowance for Mexican Patent ... by NeuroSigma and the Regents of the University ...
(Date:11/2/2014)... month,s issue of Physics World , James Dacey ... "valley of death" to take their innovations from the ... the gruelling challenge facing all start-up companies as they ... physicists because of two main factors: physics-based inventions are ... often turn out to be a lot more complicated ...
Breaking Biology News(10 mins):Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3The 'valley of death' facing physics start-ups 2
... October 15,2012 Curabitur molestie mauris sed dolor ... urna. Duis dictum, purus in condimentum tincidunt, nisl lacus porta ... ipsum dolor sit amet, consectetur adipiscing elit. Mauris est velit, ... ac risus cursus mattis nec ut erat. Donec fringilla dapibus ...
... Oct. 16, 2012 MedNet Solutions, a global life ... systems, and Statistics & Data Corporation (SDC), a specialized ... and data management services to the life sciences industry, ... iMedNet ™ EDC platform ...
... Inc. announced that it has signed an agreement ... offer the Covaris M220 Focused-ultrasonicator system to users ... Compact, cost effective, easy-to-use, and quiet; the M220 ... and Proton™ users. The M220 includes integrated cooling, ...
Cached Biology News:Statistics & Data Corporation Selects MedNet Solutions As Strategic Technology Partner 2Statistics & Data Corporation Selects MedNet Solutions As Strategic Technology Partner 3
Tracker Datamatrix RS-1* reads 96 2D Bar-coded tubes within 20 seconds....
Hybridization cassette for one slide...
Complete cell culture media with cytokines...
Request Info...
Biology Products: